U.S. Markets closed

Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session

Zacks Equity Research

Aurinia Pharmaceuticals Inc. AUPH was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $6.10–$7.09 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen no estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Aurinia Pharmaceuticals currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is negative.

Aurinia Pharmaceuticals Inc Price and Consensus

Aurinia Pharmaceuticals Inc Price and Consensus | Aurinia Pharmaceuticals Inc Quote

Another stock that warrants a look in the Medical - Drugs industry is MEI Pharma, Inc.MEIP which also carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AUPH going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
MEI Pharma, Inc. (MEIP) : Free Stock Analysis Report
 
Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research